Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Cash from Financing Activities (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Cash from Financing Activities for 7 consecutive years, with $15.5 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 791.51% to $15.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58.8 million through Dec 2025, up 126.11% year-over-year, with the annual reading at $45.0 million for FY2025, 25.43% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $15.5 million at Outlook Therapeutics, up from $11.6 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $18.4 million in Q1 2025, with the low at $1.7 million in Q4 2024.